KMT2A and acute lymphoblastic leukemia: Promising preclinical data of Flt3 inhibitors in MLL-rearranged ALL have prompted a Phase III trial in which newly diagnosed infants are randomized to receive combination chemotherapy plus or minus Lestaurtinib (39, 105).